Cencora, Inc. $COR Shares Bought by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC increased its position in shares of Cencora, Inc. (NYSE:COR) by 3.7% during the third quarter, Holdings Channel reports. The institutional investor owned 45,863 shares of the company’s stock after buying an additional 1,654 shares during the quarter. Cencora comprises about 0.8% of Knights of Columbus Asset Advisors LLC’s portfolio, making the stock its 24th largest holding. Knights of Columbus Asset Advisors LLC’s holdings in Cencora were worth $14,334,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in COR. Atlantic Edge Private Wealth Management LLC boosted its holdings in Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares in the last quarter. Vermillion & White Wealth Management Group LLC grew its position in shares of Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares during the last quarter. Cloud Capital Management LLC acquired a new stake in Cencora during the 3rd quarter worth $31,000. Copia Wealth Management grew its stake in Cencora by 505.0% during the 3rd quarter. Copia Wealth Management now owns 121 shares of the company’s stock worth $38,000 after buying an additional 101 shares during the last quarter. Finally, Caldwell Trust Co purchased a new position in shares of Cencora during the second quarter worth approximately $46,000. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

COR has been the subject of a number of recent research reports. Mizuho increased their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Bank of America lowered their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. TD Cowen boosted their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Wells Fargo & Company increased their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, Barclays started coverage on Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $393.08.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. The trade was a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 20,316 shares of company stock worth $7,151,265. 0.38% of the stock is owned by insiders.

Cencora Stock Performance

Shares of COR stock opened at $351.49 on Friday. The stock has a market cap of $68.19 billion, a PE ratio of 44.21, a P/E/G ratio of 1.67 and a beta of 0.66. Cencora, Inc. has a 1 year low of $237.71 and a 1 year high of $377.54. The stock has a fifty day moving average price of $347.75 and a 200 day moving average price of $323.44. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the previous year, the firm posted $3.34 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Sell-side analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date was Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.